1 | LLOYD R,OSAMURA R,KLOPPEL G,et al.WHO classification of tumours: pathology and genetics of tumours of endocrine organs[M].4th ed.Lyon: IARC Press,2017. |
2 | AKAISHI J, KONDO T, SUGINO K, et al. Prognostic impact of the Turin criteria in poorly differentiated thyroid carcinoma[J]. World J Surg, 2019, 43(9): 2235-2244. |
3 | ZHU Y, LI Y Q, JUNG C K, et al. Histopathologic assessment of capsular invasion in follicular thyroid neoplasms-an observer variation study[J]. Endocr Pathol, 2020, 31(2): 132-140. |
4 | 罗定远, 廖健伟. 甲状腺癌基因检测与临床应用广东专家共识(2020版)[J]. 中华普通外科学文献(电子版), 2020, 14(3): 161-168. |
5 | DE MATOS L L,BDEL GIGLIO A, MATSUBAYASHI C O,et al. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions:systematic review and diagnostic meta-analysis[J]. Diagn Pathol, 2012, 7: 97. |
6 | BALOCH Z, METE O, ASA S L. Immunohistochemical biomarkers in thyroid pathology[J]. Endocr Pathol, 2018, 29(2): 91-112. |
7 | HOFMAN V, LASSALLE S, BONNETAUD C,et al.Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility[J]. Virchows Arch, 2009, 455(1): 21-33. |
8 | 冯耀霞, 张 岚, 李群锋, 等. 恶性潜能未定的高分化甲状腺肿瘤中CK19、Galectin-3、HBME-1和TPO的表达及意义[J]. 实用肿瘤杂志, 2017, 32(4): 362-366. |
9 | ZHU H, QI J P, WANG Y W, et al. Hyalinizing trabecular tumor and papillary carcinoma of the thyroid[J]. Chin Med J (Engl), 2010, 123(20): 2832-2835. |
10 | SUNG S Y, SHEN H Y, HSIEH C B, et al. Hyalinizing trabecular tumor of thyroid: does frozen section prevent unnecessarily aggressive operation? Six new cases and a literature review[J]. J Chin Med Assoc, 2014, 77(11): 573-577. |
11 | 任配友, 刘 嘉, 王培松, 等. 甲状腺透明变梁状肿瘤研究进展[J]. 中国肿瘤临床, 2015, 42(15): 774-777. |
12 | HIROKAWA M, SHIMIZU M, MANABE T, et al. Hyalinizing trabecular adenoma of the thyroid: its unusual cytoplasmic immunopositivity for MIB1[J]. Pathol Int, 1995, 45(5): 399-401. |
13 | TAKADA N, HIROKAWA M, OHBAYASHI C, et al. Re-evaluation of MIB-1 immunostaining for diagnosing hyalinizing trabecular tumour of the thyroid: semi-automated techniques with manual antigen retrieval are more accurate than fully automated techniques[J]. Endocr J, 2018, 65(2): 239-244. |
14 | FU G D, POLYAKOVA O, MACMILLAN C, et al. Programmed death-ligand 1 expression distinguishes invasive encapsulated follicular variant of papillary thyroid carcinoma from noninvasive follicular thyroid neoplasm with papillary-like nuclear features[J]. EBioMedicine, 2017, 18: 50-55. |
15 | 程若川,杨婷婷.2016版中国甲状腺微小乳头状癌诊断与治疗专家共识解读[J].中国实用内科杂志,2019,39(4):351-357. |
16 | JINIH M, FOLEY N, OSHO O, et al. BRAFV600E mutation as a predictor of thyroid malignancy in indeterminate nodules: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2017, 43(7):1219-1227. |
17 | BYCHKOV A, JUNG C K, LIU Z Y, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice: perspectives for surgical pathology and cytopathology[J]. Endocr Pathol, 2018, 29(3): 276-288. |
18 | ZHAO L N, DIAS-SANTAGATA D, SADOW P M, et al. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma[J]. Cancer Cytopathol, 2017, 125(5): 323-331. |
19 | CHO U, METE O, KIM M H, et al. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features[J]. Mod Pathol, 2017,30(6): 810-825. |
20 | LEE S E, HWANG T S, CHOI Y L, et al. Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAFV600E mutation[J]. Thyroid, 2017, 27(6): 802-810. |
21 | NIKIFOROV Y E, BALOCH Z W, HODAK S P, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features[J]. JAMA Oncol, 2018, 4(8): 1125-1126. |
22 | CANCER GENOME ATLAS RESEARCH NETWORK. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690. |
23 | HOWELL G M, HODAK S P, YIP L. RAS mutations in thyroid cancer[J]. Oncologist, 2013, 18(8): 926-932. |
24 | 魏 佳, 王瑶琪, 孙 旭, 等. 甲状腺癌相关基因及其在临床诊断中应用的研究进展[J]. 吉林大学学报(医学版), 2018, 44(4): 880-885. |
25 | 黑利娟, 王娟红, 魏 威, 等. 乳头状甲状腺癌患者血清和甲状腺组织中白细胞介素6水平的检测及其意义[J]. 吉林大学学报(医学版), 2019, 45(3): 601-605. |
26 | ZAJKOWSKA K, KOPCZY?SKI J, Gó?D? S, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity[J]. Endocr Connect, 2020, 9(3): R47-R58. |
27 | JOHNSON D N, FURTADO L V, LONG B C, et al. Noninvasive follicular thyroid neoplasms with papillary-like nuclear features are genetically and biologically similar to adenomatous nodules and distinct from papillary thyroid carcinomas with extensive follicular growth[J]. Arch Pathol Lab Med, 2018, 142(7): 838-850. |
28 | RAVELLA L, LOPEZ J, DESCOTES F, et al. Preoperative role of RAS or BRAF K601E in the guidance of surgery for indeterminate thyroid nodules[J]. World J Surg, 2020, 44(7): 2264-2271. |
29 | PAULSON V A, SHIVDASANI P, ANGELL T E, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features accounts for more than half of “carcinomas” harboring RAS mutations[J]. Thyroid, 2017, 27(4): 506-511. |
30 | HORN S, FIGL A, RACHAKONDA P S, et al. TERT promoter mutations in familial and sporadic melanoma[J]. Science, 2013, 339(6122): 959-961. |
31 | LIU R Y, XING M Z. TERT promoter mutations in thyroid cancer[J]. Endocr Relat Cancer, 2016, 23(3): R143-R155. |
32 | LIU X L, BISHOP J, SHAN Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers[J]. Endocr Relat Cancer, 2013, 20(4): 603-610. |
33 | HYSEK M, PAULSSON J O, JATTA K, et al. Clinical routine TERT promoter mutational screening of follicular thyroid tumors of uncertain malignant potential (FT-UMPs):a useful predictor of metastatic disease[J].Cancers (Basel), 2019, 11(10): E1443. |
34 | PAULSSON J O, MU N N, SHABO I, et al. TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours[J]. Endocr Relat Cancer, 2018, 25(7): 723-733. |
35 | JETTEN A M. GLIS1-3 transcription factors: critical roles in the regulation of multiple physiological processes and diseases[J]. Cell Mol Life Sci, 2018, 75(19): 3473-3494. |
36 | NIKIFOROVA M N, NIKITSKI A V, PANEBIANCO F, et al. GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland[J]. Thyroid, 2019, 29(2): 161-173. |
37 | MARCHIò C, CRUZ PAULA ADA, GULARTE-MERIDA R, et al. PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid[J]. Mod Pathol, 2019, 32(12): 1734-1743. |
38 | 马晶晶, 章 涛. PPARγ功能与疾病关系研究进展[J]. 中国药理学通报, 2012, 28(5): 601-604. |
39 | CHU Y H, SADOW P M. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances[J].Semin Diagn Pathol,2020,37(5):213-218. |
40 | GHAFOURI-FARD S, SHIRVANI-FARSANI Z, TAHERI M. The role of microRNAs in the pathogenesis of thyroid cancer[J]. Noncoding RNA Res, 2020, 5(3): 88-98. |
41 | LABOURIER E, SHIFRIN A, BUSSENIERS A E, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology[J]. J Clin Endocrinol Metab, 2015, 100(7): 2743-2750. |
42 | JACQUES C,GUILLOTIN D, FONTAINE J F,et al. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors[J]. J Clin Endocrinol Metab, 2013, 98(5): E981-E989. |
43 | JAHANBANI I, AL-ABDALLAH A, ALI R H, et al. Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features[J]. Thyroid, 2018, 28(3): 319-327. |
44 | BORRELLI N, DENARO M, UGOLINI C, et al. miRNA expression profiling of ‘noninvasive follicular thyroid neoplasms with papillary-like nuclear features’ compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas[J]. Mod Pathol, 2017, 30(1): 39-51. |
45 | DENARO M, UGOLINI C, POMA A M, et al. Differences in miRNA expression profiles between wild-type and mutated NIFTPs[J]. Endocr Relat Cancer, 2017, 24(10): 543-553. |
46 | LASSALLE S, HOFMAN V, ILIE M, et al. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?[J]. Endocr Relat Cancer, 2011, 18(5): 579-594. |
47 | SHEU S Y, VOGEL E, WORM K, et al. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma[J]. Histopathology, 2010, 56(5): 632-640. |
48 | DUAN H L, LIU X D, REN X Y, et al. Mutation profiles of follicular thyroid tumors by targeted sequencing[J]. Diagn Pathol, 2019, 14(1): 39. |
49 | LAMBA SAINI M, WEYNAND B, RAHIER J, et al. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential[J]. Diagn Pathol, 2015, 10: 32. |
50 | SALVATORE G, CHIAPPETTA G, NIKIFOROV Y E, et al. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations[J]. Eur J Cancer, 2005, 41(5): 816-821. |
51 | KAKUDO K. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules[J]. Gland Surg, 2018, 7(): S8-S18. |
52 | XU B, TALLINI G, SCOGNAMIGLIO T, et al. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features[J]. Thyroid, 2017, 27(4): 512-517. |
53 | QIU Z L, SHEN C T, SUN Z K, et al. Distant metastases from pathologically proven benign follicular nodules of the thyroid: clinicopathological features and predictors of long-term survival[J].Endocrine,2020,69(1):113-125. |